Product Description
Overall, the global drug-eluting stent market was valued at $105.6 million in 2022. This is expected to increase over the forecast period at a CAGR of 1.8% to reach $119.6 million.
The full report suite on the global market for drug-eluting stents focuses on drug-eluting stents only and does not include the market’s extended set.
MARKET DATA INCLUDED
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- COVID-19 Impact Analysis
- Market Drivers & Limiters
- Market Forecasts Until 2029, and Historical Data to 2019
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
GLOBAL DRUG-ELUTING STENT MARKET INSIGHTS
The most important driver for this market is the lack of competition. Intersect ENT is the only competitor in the market. The monopoly the company has makes it possible to keep the selling price at higher levels, which will drive up the market.
GLOBAL DRUG-ELUTING STENT MARKET SHARE INSIGHTS
The Global drug-eluting stent market was controlled by Intersect ENT.
Intersect ENT held a monopoly in the drug-eluting stent market with its Propel®family. The Propel® family of products is indicated to be used in conjunction with ethmoid sinus surgery. The different shapes and sizes of the three options have been designed to accommodate different sinus anatomies. The company also offers Sinuva® Sinus Implant.Sinuva® is used for the treatment of nasal polyps in patients who have undergone a previous ethmoid sinus surgery. Both Propel® and Sinuva® implants elute the corticosteroid mometasone furoate.
MARKET SEGMENTATION SUMMARY
- ENT Drug-Eluting Stent Market – MedCore
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.) Central & Eastern Europe (Baltic States, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam) Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2022 |
| Forecast Period | 2023-2029 |
| Historical Data | 2019-2022 |
| Quantitative Data | Market Size, Market Share, Market Growth Rates, Units Sold, Average Selling Prices |
| Qualitative Data | COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data.
Read more about iData’s 9-Step Research Methodology |
WHY CHOOSE IDATA?
- Experts Only – iData has been around for over 17 years and is the trusted source of intelligence, and data-driven insights for key industry players. We are made up of specialists with a sole focus on medical devices, dental devices and pharmaceuticals. Our research and consulting field of endeavour never strays from the medical device industry and, because of this, we are the number one choice for leading companies in this field.
- Global Coverage – iData’s unique methodology, and its expansion to over 70 countries world-wide, has made it one of the most viable sources of intelligence for global companies along with those who plan to expand their portfolio beyond the confines of their own country. Providing procedural data at the country level is another testimony to the trusted global coverage we provide.
- Attention to Detail – It’s our attention to small details, scheduling of timelines, and keen project management that makes us stand out from the rest. We are creative, and our reports include metrics such as procedure numbers, ASPs, and SKU-level insights that are not found elsewhere.
- Pricing – When comparing like-with-like, iData’s prices are not only extremely competitive but also the most cost-effective. We strive for success and want the same for our clients. With the level of detail incorporated into each report alongside the extensive segmentation provided, no other report compares at our price point.
